Nelarabine, cyclosphosphamide and etoposide for adults with relapsed T-cell acute lymphoblastic leukaemia and lymphoma

Br J Haematol. 2016 Jul;174(2):332-4. doi: 10.1111/bjh.13771. Epub 2015 Sep 25.

Authors

Marlise R Luskin¹, Alex Ganetsky², Daniel J Landsburg¹, Alison W Loren¹, David L Porter¹, Sunita D Nasta¹, Jakub Svoboda¹, Selina M Luger¹, Noelle V Frey³

Affiliations

¹ Abramson Cancer Center and the Division of Hematology and Oncology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.
² Department of Pharmacy, Hospital of the University of Pennsylvania, Philadelphia, PA, USA.
³ Abramson Cancer Center and the Division of Hematology and Oncology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA. noelle.frey@uphs.upenn.edu.

PMID: 26403537
DOI: 10.1111/bjh.13771

No abstract available

Keywords: acute leukaemia; chemotherapy; leukaemia therapy; lymphoma.

Publication types

Letter

MeSH terms

Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Antineoplastic Combined Chemotherapy Protocols / toxicity
Arabinonucleosides / administration & dosage
Cyclophosphamide / administration & dosage
Etoposide / administration & dosage
Female
Humans
Lymphoma / complications
Lymphoma / drug therapy
Lymphoma / pathology
Male
Middle Aged
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / complications
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / drug therapy*
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / pathology
Recurrence
Salvage Therapy / adverse effects
Salvage Therapy / methods*

Substances

Arabinonucleosides
nelarabine
Etoposide
Cyclophosphamide